RESUMO
1,3-Dimethylamylamine (DMAA) is a pressor amine often found in food supplements for athletes at dosages of 25-65 mg. Historically, the compound has been used as a nasal decongestant but its oral application is largely unstudied leaving the regulatory status of such food supplements as unlicensed medicines undetermined. We therefore reviewed the literature on DMAA and similar amines in order to deduce an effective oral dosage. Based on our findings we conclude that oral preparations with >4 mg DMAA per dose unit should be considered as effective as a bronchodilator. Food supplements that exceed that limit are in fact subject to the Medicines Act and require licensing. Dosages higher than 100-200 mg are expected to cause serious adverse events.
RESUMO
La ateroesclerosis, es una enfermedad crónica, sistémica, inmuno-inflamatoria que afecta a la íntima arterial. La disfunción endotelial es la primera fase en la ateroesclerosis La disfunción endotelial está caracterizada por un daño y pérdida de la monocapa celular que cubre el interior de los vasos sanguíneos, denominada endotelio. Uno de los principales mediadores ara el mentenimieno de la integridad del endotelio, es el óxido nítrico (ON). La Dimetilarginina asimétrica (DMMA), es un inhibidor endógeno de la enzima sintasa del Óxido Nítrico (SON); se ha sugerido que DMAA sirve como un marcador de disfunción endotelial en enfermedades cardiovasculares. Asimismo, la DMAA representa un factor de riesgo para mortalidad cardiovascular, progresión de enfermedad crónica renal. Se ha encontrado valores elevados de DMAA en diferentes condiciones como hipercolesterolemia, aterosclerosis, hipertensión, insuficiencia renal crónica, insuficiencia crónica del corazón, diabetes y disfunsión eréctil.
Atherosclerosis is an immune inflammatory systemic, arterial disease. Endothelial dysfunction is the first stage in aterosclerosis. Atherosclerosis develops because of reactions occurring in vessel wall beginning with response to enothelial injury. Endothelial dysfunction is characterized with impairment and loss of monolayer cells covering the inside of the vessels, which is enothelium. One of the main mediators for the maintenance of the integrity of endothelium is Nitric Oxide (NO). The asymmtric Dimethilarginine (ADMA), is an endogenous inhibitor of the enzyme Nitric Oxide Synthase (NOS). ADMA has been suggested to serve as a biomarker of endothelial dysfunction in cardiovascular diseases. ADMA is a risk factor for endothelial dysfunction, cardiovascular mortality, and progression of chronic kidney disease. Elevated values of ADMA have been found in hypercholesterolemia, atherosclerosis, hypertension, chronic renal insufficiency, heart chronic failure, diabetes and erectile dysfunction.